Clinical Implication of Very Low Dose of Sacubitril/valsartan for Patients With Heart Failure With Reduced Ejection Fraction; Beyond PARADIGM-HF and PIONEER-HF Trial

被引：0
|
作者：
Kim, Hyoeun
Oh, Jaewon
Ha, Jaehyung
Chun, Kyeong-Hyeon
Lee, Chan Joo
Park, Sungha
Lee, Sang-Hak
Kang, Seok-Min
机构：
来源：
CIRCULATION | 2019年 / 140卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A10616
引用
收藏
页数：2
相关论文
共 50 条
  • [1] VERY LOW DOSE OF SACUBITRIL/VALSARTAN FOR PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: BEYOND PARADIGM-HF TRIAL
    Kim, Hyoeun
    Oh, Jaewon
    Jang, Ji-Hun
    Kang, Seok-Min
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 955 - 955
  • [2] Clinical Role of Sacubitril/valsartan Therapy in Heart Failure With Reduced Ejection Fraction Patients With End Stage of Renal Disease; Beyond PARADIGM-HF Trial
    Lee, Seonhwa
    Oh, Jaewon
    Ha, Jaehyung
    Chun, Kyeong-Hyeon
    Kim, Hyoeun
    Lee, Chan Joo
    Park, Sungha
    Lee, Sang-Hak
    Kang, Seok-Min
    CIRCULATION, 2019, 140
  • [3] Racial Differences, Outcomes and Response to Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: PARADIGM-HF
    Lewis, Eldrin F.
    Claggett, Brian
    Solomon, Scott D.
    McMurray, John J. V.
    Swedberg, Karl
    Desai, Akshay S.
    Rouleau, Jean L.
    Zile, Michael
    Shi, Victor C.
    Lefkowitz, Martin P.
    Packer, Milton
    JOURNAL OF CARDIAC FAILURE, 2016, 22 (08) : S9 - S10
  • [4] Asymptomatic vs Symptomatic Hypotension With Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction in PARADIGM-HF
    Matsumoto, Shingo
    Shen, Li
    Henderson, Alasdair D.
    Boehm, Michael
    Desai, Akshay S.
    Kober, Lars
    Lefkowitz, Martin P.
    Packer, Milton
    Rouleau, Jean L.
    Solomon, Scott D.
    Swedberg, Karl
    Vaduganathan, Muthiah
    Vardeny, Orly
    Voors, Adriaan A.
    Zile, Michael R.
    Jhund, Pardeep S.
    McMurray, John J., V
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (18) : 1685 - 1700
  • [5] Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction
    Fudim, Marat
    Sayeed, Sabina
    Xu, Haolin
    Matsouaka, Roland A.
    Heidenreich, Paul A.
    Velazquez, Eric J.
    Yancy, Clyde W.
    Fonarow, Gregg C.
    Hernandez, Adrian F.
    DeVore, Adam D.
    CIRCULATION-HEART FAILURE, 2020, 13 (04)
  • [6] Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial
    Vardeny, Orly
    Claggett, Brian
    Packer, Milton
    Zile, Michael R.
    Rouleau, Jean
    Swedberg, Karl
    Teerlink, John R.
    Desai, Akshay S.
    Lefkowitz, Martin
    Shi, Victor
    McMurray, John J. V.
    Solomon, Scott D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 (10) : 1228 - 1234
  • [7] Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial
    Bouabdallaoui, Nadia
    Claggett, Brian
    Zile, Michael R.
    McMurray, John J. V.
    O'Meara, Eileen
    Packer, Milton
    Prescott, Margarett F.
    Swedberg, Karl
    Solomon, Scott D.
    Rouleau, Jean L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 (12) : 1701 - 1709
  • [8] Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial
    Morrow, David A.
    Velazquez, Eric J.
    DeVore, Adam D.
    Desai, Akshay S.
    Duffy, Carol I.
    Ambrosy, Andrew P.
    Gurmu, Yared
    McCague, Kevin
    Rocha, Ricardo
    Braunwald, Eugene
    CIRCULATION, 2019, 139 (19) : 2285 - 2288
  • [9] Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial
    Berg, David D.
    Braunwald, Eugene
    DeVore, Adam D.
    Lala, Anuradha
    Pinney, Sean P.
    Duffy, Carol, I
    Gurmu, Yared
    Velazquez, Eric J.
    Morrow, David A.
    JACC-HEART FAILURE, 2020, 8 (10) : 834 - 843
  • [10] Reduced Risk of Hyperkalemia in Heart Failure Patients Treated With an MRA and Sacubitril/Valsartan Compared With Enalapril: The PARADIGM-HF Trial
    Solomon, Scott
    Packer, Milton
    Claggett, Brian
    Vardeny, Orly
    Zile, Michael
    Swedberg, Karl
    Rouleau, Jean
    Shi, Victor
    Lefkowitz, Martin
    McMurray, John
    CIRCULATION, 2016, 134
12345